论文部分内容阅读
目的:制备美洛昔康固体脂质纳米粒,并考察其透皮吸收行为。方法:采用热熔乳化超声-低温固化法制备美洛昔康固体脂质纳米粒,并考察其包封率、粒径分布、Zeta电位、微观形态及体外药物释放特性,采用Franz扩散池考察其透皮吸收行为。结果:美洛昔康固体脂质纳米粒的包封率为(85.6±2.7)%,平均粒径为(213.5±52.6)nm,Zeta电位为(-32.2±3.9)m V,透射电镜显示美洛昔康固体脂质纳米粒粒径均一,成球状分布。其12 h药物累积透皮量显著高于美洛昔康溶液。结论:美洛昔康固体脂质纳米粒可以显著提高药物累积透皮量,有望成为美洛昔康的新型局部给药制剂。
Objective: To prepare meloxicam solid lipid nanoparticles and study its transdermal absorption behavior. Methods: Meloxicam solid lipid nanoparticles were prepared by hot-melt emulsification ultrasound-low temperature curing method. The encapsulation efficiency, particle size distribution, Zeta potential, microscopic morphology and in vitro drug release properties were determined. Franz diffusion cells Transdermal absorption behavior. Results: The encapsulation efficiency of meloxicam solid lipid nanoparticles was (85.6 ± 2.7)%, the average particle diameter was (213.5 ± 52.6) nm and the zeta potential was (-32.2 ± 3.9) mV. Loslconazole solid lipid nanoparticles uniform particle size, into a spherical distribution. The cumulative transdermal dose of 12 h drug was significantly higher than that of meloxicam solution. Conclusion: Meloxicam solid lipid nanoparticles can significantly increase the cumulative amount of transdermal drug, which is expected to become a new topical meloxicam preparation.